Q-omics provides the consensus-scored PRDX2 profile across patient tissues and cancer cell-line models. PRDX2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRDX2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PRDX2 protein abundance shows 19,343 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, COAD, and CCRCC as cancer lineages where PRDX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX2 survival associations across molecular data types. PRDX2 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX2 RNA expression–survival associations across cancer types. High PRDX2 expression shows unfavorable associations in ACC and UCS, but favorable associations in KIRC, LUSC, KIRP and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRDX2 RNA expression.
This table summarizes PRDX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRDX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX2 shows lower tumor expression in KIRC and HNSC and higher tumor expression in COAD, LIHC, LUSC and UCEC. The COAD box plot shows higher PRDX2 RNA expression in tumor versus normal tissue (log2 FC = +0.881, t-test p < 0.001).
This table shows molecular features associated with PRDX2 in patient tissues and cancer cell lines. In patient samples, PRDX2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
